



24 December 2020

ASX ANNOUNCEMENT

**NOTICE UNDER SECTION 708A OF THE CORPORATIONS ACT**

This notice is given by Cynata Therapeutics Limited (the **Company**) pursuant to section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company has today issued 14,285,715 fully paid ordinary shares at an issue price of \$0.70 per share (**Shares**) in accordance with the terms of a placement to professional and sophisticated investors announced to ASX on 11 December 2020 (**Placement**).

Pursuant to paragraph 708A(5)(e) of the Corporations Act, the Company gives notice that:

1. the Company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
  - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (b) section 674 of the Corporations Act; and
3. as at the date of this notice, there is no information that is “excluded information” (as defined in section 708A(7) of the Corporations Act) which is required to be disclosed by the Company.

The balance of the shares to be issued under the Placement (representing 224,120 Shares) will be issued at the time of settlement of that component of the Placement, which is expected to occur in calendar 2020.

Authorised by

A handwritten signature in blue ink, appearing to read "Ross Macdonald", written over a light blue horizontal line.

**Ross Macdonald**  
Managing Director & CEO

Contacts: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119 343,  
[ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Claire LaCagnina, U.S. Media Contact, + 315.765.1462,  
[clacagnina@6degreespr.com](mailto:clacagnina@6degreespr.com)